Holen Sie sich die Stockscreener-App
22.48
3.23%
-0.75
Schlusskurs vom Vortag:
$23.23
Offen:
$23.42
24-Stunden-Volumen:
407.41K
Relative Volume:
0.55
Marktkapitalisierung:
$1.67B
Einnahmen:
$105.97M
Nettoeinkommen (Verlust:
$-81.13M
KGV:
-20.83
EPS:
-1.0791
Netto-Cashflow:
$-35.43M
1W Leistung:
-6.64%
1M Leistung:
-0.53%
6M Leistung:
+42.82%
1J Leistung:
+79.12%
1-Tages-Spanne:
$22.43
$23.89
1-Wochen-Bereich:
$22.43
$28.00
52-Wochen-Spanne:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
22.44 | 1.73B | 105.97M | -81.13M | -35.43M | -1.0791 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.45 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.75 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.81 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Value Recap: Does Zymeworks Inc have strong EBITDA marginsTrade Analysis Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Zymeworks (NASDAQ:ZYME) Trading Up 9.7%What's Next? - MarketBeat
Zymeworks (ZYME) Price Target Raised to $48 by Evercore ISI Grou - GuruFocus
Will Zymeworks' (ZYME) Wider Losses and ESOP Shelf Offering Recast Its Long-Term Equity Story? - Sahm
Zymeworks (NASDAQ:ZYME) Price Target Raised to $46.00 - MarketBeat
Zymeworks (ZYME) Rating Maintained, Price Target Raised to $46 b - GuruFocus
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat
Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga
Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus
Stifel raises Zymeworks stock price target on royalty deal value By Investing.com - Investing.com Canada
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com Nigeria
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Australia
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience By GuruFocus - Investing.com Canada
Zymeworks (ZYME) EPS Loss In Q3 2025 Tests Bullish Profitability Narratives - Sahm
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com Canada
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com South Africa
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Zymeworks Q4 2025 shows revenue growth, net loss reduction - Investing.com UK
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens - AlphaStreet
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Zymeworks Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-03-02 - Seeking Alpha
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Koreabizwire
Zymeworks Reports FY25 Results, Secures $250 Million Royalty Financing - Nasdaq
Zymeworks Monetizes Ziihera Royalties to Boost Liquidity - TipRanks
Zymeworks Posts Strong 2025 Growth and Bolsters Liquidity - TipRanks
Zymeworks 2025 10-K: $106M Revenue, $(1.08) EPS - TradingView
Zymeworks Inc. Q4 Loss Widens - Nasdaq
Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing - Stock Titan
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma - Nasdaq
Zymeworks Inc. Reports Financial Results for 2025 and Updates on Ziihera® Development and Strategic Plans - Quiver Quantitative
$250M cancer drug royalty deal extends Zymeworks’ cash runway - Stock Titan
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Aug Levels: How sensitive is Zymeworks Inc to inflationMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn
A Look Ahead: Zymeworks's Earnings Forecast - Benzinga
Zymeworks Inc. (ZYME) Stock Analysis: Biotech Innovator With 56% Potential Upside - DirectorsTalk Interviews
Does Zymeworks Inc stock have upside surprise potential2025 Market Sentiment & Accurate Intraday Trade Tips - baoquankhu1.vn
Zymeworks (ZYME) Form 144 shows insider sell request of 31,641 shares - Stock Titan
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):